CTLA4 haploinsufficiency caused by a novel heterozygous splice site mutation
Abstract
Background: Cytotoxic T lymphocyte-associated antigen-4 (CTLA4) haploinsufficiency is characterized by a variety of phenotypes, ranging from autoimmune disorders, enteropathy, fatal combined immunodeficiency, as well as lymphoproliferation and malignancy.
Aim: To broaden the genotypic spectrum and clinical presentations of patients with CTLA4 variants.
Methods: We evaluated a female patient with autoimmunity and lymphopenia. Immune workup and whole exome sequencing (WES) were performed.
Results: The proband presented at 11 years of age with hypothyroidism and later developed Evans syndrome, alopecia, eczema, and lymphocytic interstitial pneumonia. Immune evaluation revealed T, B, and NK lymphopenia with normal humoral immunity. Following a negative genetic panel for autoimmune lymphoproliferative syndrome (ALPS), WES analysis identified a novel heterozygous intronic variant predicted in-silico to cause skipping of exon 2 of the CTLA4 gene.
Conclusion: A novel heterozygous mutation in CTLA4 caused variable presentations of immune dysregulation, one of the hallmarks of CTLA4 haploinsufficiency.
Statement of Novelty: We herein report a novel mutation in CTLA4 resulting in various features of autoimmunity.
Formats available
You can view the full content in the following formats:
REFERENCES
Cunningham-Rundles, C. 2010. How I treat common variable immune deficiency. Blood, 116(1): 7 [online]. Available from /pmc/articles/PMC2904582/ [accessed 5 April 2022].
Egg D., Rump I.C., Mitsuiki N., Rojas-Restrepo J., Maccari M.E., Schwab C., Gabrysch A., Warnatz K., Goldacker S., Patiño V., Wolff D., Okada S., Hayakawa S., Shikama Y., Kanda K., Imai K., Sotomatsu M., Kuwashima M., Kamiya T., Morio T., Matsumoto K., Mori T., Yoshimoto Y., Dybedal I., Kanariou M., Kucuk Z.Y., Chapdelaine H., Petruzelkova L., Lorenz H.M., Sullivan K.E., Heimall J., Moutschen M., Litzman J., Recher M., Albert M.H., Hauck F., Seneviratne S., Schmid P.J, Kolios A., Unglik G., Klemann C., Snapper S., Giulino-Roth L., Svaton M., Platt C.D., Hambleton S., Neth O., Gosse G., Reinsch S., Holzinger D., Kim Y.J., Bakhtiar S., Atschekzei F., Schmidt R., Sogkas G., Chandrakasan S., Rae W., Derfalvi B., Marquart H.V., Ozen A., Kiykim A., Karakoc-Aydiner E., Králíčková P., de Bree G., Kiritsi D., Seidel M.G., Kobbe R., Dantzer J., Alsina L., Armangue T., Lougaris V., Agyeman P., Nyström S., Buchbinder D., Arkwright P.D., and Grimbacher B. 2021. Therapeutic options for CTLA-4 insufficiency. Trans. Clinical Immunol. 149(2): 736–746. [accessed 5 April 2022].
Hayakawa S., Okada S., Tsumura M., Sakata S., Ueno Y., Imai K., Morio T., Ohara O., Chayama K., and Kobayashi M. 2016. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer. J. Clinical Immunol. 36(1): 28–32.
Kuehn H.S., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T., Schickel J-N., Tran D.Q., Stoddard J., Zhang Y., Frucht D.M., Dumitriu B., Scheinberg P., Folio L.R., Frein C.A., Price S., Koh C., Heller T., Seroogy C.M., Huttenlocher A., Rao V.K., Su H.C., Kleiner D., Notarangelo L.D., Rampertaap Y., Olivier K.N., McElwee J., Hughes J., Pittaluga S., Oliveira J.B., Meffre E., Fleisher T.A., Holland S.M., Lenardo M.J., Tangye S.G., and Uzel G. 2014. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science, 345(6204): 1623–1627.
Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J.M., Marsh, R., Husami, A., Kissell, D., Nortman, S., Chaturvedi, V., Haines, H., Young, L.R., Mo, J., Filipovich, A.H., Bleesing, J.J., Mustillo, P., Stephens, M., Rueda, C.M., Chougnet, C.A., Hoebe, K., McElwee, J., Hughes, J.D., Karakoc-Aydiner, E., Matthews, H.F., Price, S., Su, H.C., Rao, V.K., Lenardo, M.J., and Jordan, M.B. 2015. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science (New York, N.Y.) 349(6246): 436–440 [online]. Available from https://pubmed.ncbi.nlm.nih.gov/26206937/ [accessed 30 April 2022].
Mahat, U., Ambani, N.M., Rotz, S.J., and Radhakrishnan, K. 2021. Heterozygous CTLA4 splice site mutation c.458-1G > C presenting with immunodeficiency and variable degree of immune dysregulation in three generation kindred of Caribbean descent. Pediatr. Hematol. Oncol. 38(7): 658–662 [online]. Available from https://www.tandfonline.com/action/journalInformation?journalCode=ipho20 [accessed 3 April 2022].
Rosenzweig, S., Maffucci1, P., Filion, C.A., Boisson, B., Itan, Y., Shang, L., Casanova, J.-L., and Cunningham-Rundles, C. 2016. Article 220 1 Maffucci et al. Genetic Diagnosis Using WES in CVID Frontiers in Immunology | www. 7, p. 220. [online]. Available from www.frontiersin.org.
Schubert D., Bode C., Kenefeck R., Hou T.Z., Wing J.B., Kennedy A., Bulashevska A., Petersen B.-S., Schäffer A.A., Grüning B.A., Unger S., Frede N., Baumann U., Witte T., Schmidt R.E., Dueckers G., Niehues T., Seneviratne S., Kanariou M., Speckmann C., Ehl S., Rensing-Ehl A., Warnatz K., Rakhmanov M., Thimme R., Hasselblatt P., Emmerich F., Cathomen T., Backofen R., Fisch P., Seidl M., May A., Schmitt-Graeff A., Ikemizu S., Salzer U., Franke A., Sakaguchi S., Walker L.S.K., Sansom D.M., and Grimbacher B. 2014. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat. Med. 20(12): 1410–1416.
Schwab C., Schwab C., Gabrysch A., Olbrich P., Patiño V., Warnatz K., Wolff D., Hoshino A., Kobayashi M., Imai K., Takagi M., Dybedal I., Haddock J.A., Sansom D.M., Lucena J.M., Seidl M., Schmitt-Graeff A., Reiser V., Emmerich F., Frede N., Bulashevska A., Salzer U., Schubert D., Hayakawa S., Okada S., Kanariou M., Kucuk Z.Y., Chapdelaine H., Petruzelkova L., Sumnik Z., Sediva A., Slatter M., Arkwright P.D., Cant A., Lorenz H-M., Giese T., Lougaris V., Plebani A., Price C., Sullivan K.E., Moutschen M., Litzman J., Freiberger T., van de Veerdonk F.L., Recher M., Albert M.H., Hauck F., Seneviratne S., Schmid J.P., Kolios A., Unglik G., Klemann C., Speckmann C., Ehl S., Leichtner A., Blumberg R., Franke A., Snapper S., Zeissig S., Cunningham-Rundles C., Giulino-Roth L., Elemento O., Dückers G., Niehues T., Fronkova E., Kanderová V., Platt C.D., Chou J., Chatila T.A., Geha R., McDermott E., Bunn S., Kurzai M., Schulz A., Alsina L., Casals F., and Deyà-Martinez A. 2018. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. J. Allergy Clinical Immunol. 142(6): 1932–1946.
Sun H., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T., Schickel J-N., Tran D.Q., Stoddard J., Zhang Y., Frucht D.M., Dumitriu B., Scheinberg P., Folio L.R., Frein C.A., Price S., Christopher Koh S., Heller T., Seroogy C.M., Huttenlocher A., Rao V.K., Su H.C., Kleiner D., Notarangelo L.D., Rampertaap Y., Olivier K.N., McElwee J., Hughes J., Pittaluga S., Oliveira J.B., Meffre E., Fleisher T.A., Holland S.M., Lenardo M.J., Tangye S.G., and Uzel G. 2014. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 HHS Public Access. Science, 345(6204): 1623–1627.
Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., and Sharpe, A.H. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immun. 3(5): 541–547. [online]. Available from https://pubmed.ncbi.nlm.nih.gov/7584144/ [accessed 30 April 2022].
Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., Thompson, C.B., Griesser, H., and Mak, T.W. 1995. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4. Science, 270(5238): 985–988 [online]. Available from https://www.science.org/doi/abs/10.1126/science.270.5238.985 [accessed 30 April 2022].
Information & Authors
Information
Published In
LymphoSign Journal
Volume 9 • Number 2 • June 2022
Pages: 40 - 44
History
Received: 3 May 2022
Accepted: 15 May 2022
Accepted manuscript online: 19 May 2022
Version of record online: 19 May 2022
Copyright
© 2022.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
JennyGarkaby, Laura EdithAbrego Fuentes, JessicaWillett Pachul, and LindaVong. 2022. CTLA4 haploinsufficiency caused by a novel heterozygous splice site mutation. LymphoSign Journal.
9(2): 40-44. https://doi.org/10.14785/lymphosign-2022-0004
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
